Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Burchert

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Current Hematologic Malignancy Reports|February 7, 2014
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistenceAndreas Burchert
Haematologica|January 21, 2021
Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemiaAndreas Burchert
Zeitschrift Fur Gerontologie Und Geriatrie|January 20, 2023
[Clonal hematopoiesis: causes and clinical implications]Andreas Burchert
Innere Medizin (Heidelberg, Germany)|August 15, 2022
[Clonal hematopoiesis: causes and clinical implications]Andreas Burchert
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 9, 2007
Roots of imatinib resistance: a question of self-renewal?Andreas Burchert
Leukemia & Lymphoma|December 29, 2004
Interferon alpha and T-cell responses in chronic myeloid leukemiaAndreas Burchert, Andreas Neubauer
Leukemia|May 26, 2026
Response to: Potential impact of NK-cell education on interferon efficacy in the ENDURE trialAndreas Burchert, Christian Michel
Innere Medizin (Heidelberg, Germany)|July 11, 2025
[CAR T-cell therapy of mature B-cell neoplasms-Current use and practical considerations]Theresa Weber, Andreas Burchert, Marion Subklewe
Leukemia & Lymphoma|June 28, 2011
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemiaChristian Wilhelm, Andreas Neubauer, Andreas Burchert
Blood|November 22, 2011
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibAshu Kumari, Cornelia Brendel, Andreas Hochhaus, et al.
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Current Hematologic Malignancy Reports|February 7, 2014
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistenceAndreas Burchert
Haematologica|January 21, 2021
Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemiaAndreas Burchert
Zeitschrift Fur Gerontologie Und Geriatrie|January 20, 2023
[Clonal hematopoiesis: causes and clinical implications]Andreas Burchert
Innere Medizin (Heidelberg, Germany)|August 15, 2022
[Clonal hematopoiesis: causes and clinical implications]Andreas Burchert
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 9, 2007
Roots of imatinib resistance: a question of self-renewal?Andreas Burchert
Leukemia & Lymphoma|December 29, 2004
Interferon alpha and T-cell responses in chronic myeloid leukemiaAndreas Burchert, Andreas Neubauer
Leukemia|May 26, 2026
Response to: Potential impact of NK-cell education on interferon efficacy in the ENDURE trialAndreas Burchert, Christian Michel
Innere Medizin (Heidelberg, Germany)|July 11, 2025
[CAR T-cell therapy of mature B-cell neoplasms-Current use and practical considerations]Theresa Weber, Andreas Burchert, Marion Subklewe
Leukemia & Lymphoma|June 28, 2011
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemiaChristian Wilhelm, Andreas Neubauer, Andreas Burchert
Blood|November 22, 2011
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibAshu Kumari, Cornelia Brendel, Andreas Hochhaus, et al.
Pageof 11